Applied to GBM, radiomic analysis proved to be effective in predicting IDH mutation, O6‐methylguanine‐DNA methyltransferase (MGMT) methylation and EGFRvIII mutation (Rathore et al., 2018; Vils et al., 2021), and 6‐month disease progression (Kim et al., 2019). The gene discussed is IDH1; the disease is glioblastoma.